Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Community-onset (CO) candidemia, defined as a positive blood culture taken at or within 2 days of hospital admission, represents a distinct clinical entity associated with substantial morbidity and mortality. Reference MIC results from the SENTRY Antimicrobial Surveillance Program (2008-2009) were analyzed to compare the antifungal resistance patterns and species distributions from patients with CO and nosocomial bloodstream infections (BSI) in 79 medical centers. Among 1,354 episodes of BSI, 494 (36.5%) were classified as CO and 860 (63.5%) as nosocomial in origin. More than 95% of the isolates from both BSI types were contributed by Candida albicans (48.4%), C. glabrata (18.2%), C. parapsilosis (17.1%), C. tropicalis (10.6%), and C. krusei (2.0%). C. albicans was more common in CO BSI (51.0%) than nosocomial BSI (46.9%), whereas C. parapsilosis and C. krusei were more common in nosocomial BSIs (18.1 and 2.7%, respectively) than in CO BSIs (15.4 and 0.8%, respectively). C. glabrata and C. tropicalis were comparable in both CO (18.4 and 10.5%, respectively) and nosocomial (18.1 and 10.6%, respectively) episodes. Resistance to azoles (fluconazole, posaconazole, and voriconazole) and echinocandins (anidulafungin, caspofungin, and micafungin) was uncommon (<5%) in CO BSI using recently established Clinical and Laboratory Standards Institute breakpoint criteria. Resistance to echinocandins (anidulafungin [3.8%], caspofungin [5.1%], and micafungin [3.2%]) and azoles (fluconazole [7.7%], posaconazole [5.1%], and voriconazole [6.4%]) was most prevalent among nosocomial BSI isolates of C. glabrata . CO candidemia is not uncommon and appears to be increasing worldwide due to changing health care practices. Although resistance to the azoles and echinocandins remains uncommon among CO isolates, we demonstrate the emergence of nosocomial occurrences of C. glabrata expressing resistance to both monitored classes of antifungal agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Species and drug- resistance patterns are known to vary substantially by geography, facility, and even among units within the same facility [24, 25].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With respect to CLSI clinical breakpoints, fluconazole resistance, defined as MIC values ≥8 mg/L for C. albicans, has been reported overall to be as high as 3.5%.43–48”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“Second, the increased incidence of invasive candidiasis caused by non-albicans Candida (NAC) species, such as Candida glabrata, Candida tropicalis, Candida krusei or Candida parapsilosis, has been a major concern [13], [14], because these infections are often associated with higher mortality and antifungal resistance than those caused by C. albicans [15], [16].”
From In Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections (2014) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 2×
“Hajjeh et al. (17) have shown that in 1998 through 2000, only 36% of Candida BSIs occurred in the ICU, whereas 28% were community onset (CO), an increase of almost 10% above that reported in 1992 and 1994 (19).”
ResultEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“Although much of the literature concerning IC has focused on nosocomial (NOS) bloodstream infections (BSI), especially those occurring in the intensive care unit (ICU) (3, 12, 13, 25, 27, 49), an increasing incidence of IC overall (35, 50), combined with data from the National Nosocomial Infection System survey, which…”
ResultSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 2×
“parapsilosis should be noted in light of the recommendation of the Infectious Diseases Society of America that infection with this species should be treated with either an azole or amphotericin B (lipid formulation) rather than an echinocandin (30).”
BackgroundMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Weinstein, M. P., Towns, M. L., Quartey, S. M., Mirrett, S., Reimer, L. G., Parmigiani, G., & Barth Reller, L. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.584 · Cited by 1,228
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171 · cited 1×
“It is now evident that a delay in initiating antifungal therapy in the critically ill patient is associated with compromised outcomes (an increase in mortality of 8% for each hour in which appropriate therapy is delayed), excessive costs of hospitalization, and potentially devastating complications such as endocarditi…”
BackgroundEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citationEpidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
Blumberg, H. M., Jarvis, W. R., Soucie, J. M., Edwards, J. E., Patterson, J. E., Pfaller, M. A., Rangel‐Frausto, M. S., Rinaldi, M. G., Saiman, L., Wiblin, R. T., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/321811 · Cited by 661
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Cited by
Items 201–243 of 243
Jain, N., & Fries, B. C. (2011) · Wiley eBooks · doi:10.1002/9780470015902.a0002234.pub2 · Cited by 2
Joshi, D. N., Archana, M., Gor, N. S., Bhavana, M. V., Adhikary, R., & Shenoy, B. (2025) · EMJ Microbiology & Infectious Diseases · doi:10.33590/emjmicrobiolinfectdis/hkmw5127 · Cited by 3
Clinical Relevance of In Vitro Resistance of Echinocandins: a Focus on Candida parapsilosis
Kale-Pradhan, P. B., Wilhelm, S. M., & Johnson, L. B. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0087-9 · Cited by 1
Echinocandins for Primary Therapy of Candidemia: Time for a Paradigm Shift?
Colombo, R. E., & Vázquez, J. A. (2015) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0215-9 · Cited by 2
Risk Factors and Prognosis for Persistent Candidemia without Catheter Colonization
Chae, Y. T., Jeong, S. J., Ku, N. S., Baek, J. H., Kim, H., Kim, S. B., Yoon, J. H., Jin, S. J., Han, S. H., Song, Y. G., et al. (2011) · Infection and Chemotherapy · doi:10.3947/ic.2011.43.4.349 · Cited by 1
Probiotics in Invasive Candidiasis
Colombo, J., & Arena, A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802189-7.00048-4 · Cited by 2
Candidiasis and the impact of flow cytometry on antifungal drug discovery
Ku, T. S. N., Bernardo, S. M., Walraven, C. J., & Lee, S. A. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1377179 · Cited by 1
Bagirova, N. S., & Дмитриева, Н. В. (2017) · Laboratory Service · doi:10.17116/labs201763182-189 · Cited by 1
Invasive Fungal Disease in the Transplant Population: An Overview
Saullo, J. L., Perfect, J. R., & Alexander, B. D. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_31 · Cited by 1
An Improved Scalable Preparation of the Antifungal Posaconazole
Raju, V. R. K., & Jha, A. (2021) · Organic Preparations and Procedures International · doi:10.1080/00304948.2021.1997266 · Cited by 1
Warris, A. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755388.003.0035 · Cited by 1
Bacterial and fungal infections: evolving towards molecular pathogen diagnostics
Hansen, W. L. J. (2012) · Research Publications (Maastricht University) · doi:10.26481/dis.20120620wh · Cited by 1
de Jesus, R. S. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Medical Mycology for the Hospital Epidemiologist
Barron, M. A. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0077-3
da Rosa, J. L. (2012) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/w35r-7869
iNKT Cells Participate in the Exacerbation of Systemic Candidal Infection
Tarumoto, N., Kinjo, Y., Kitano, N., Shibuya, K., Maesaki, S., & Miyazaki, Y. (2014) · Medical Mycology Journal · doi:10.3314/mmj.55.j115
Shehata, A. S. (2016) · The Egyptian Journal of Medical Microbiology · doi:10.12816/0037002
Souza, M. D., & Neufeld, P. M. (2016) · Vigilância Sanitária em Debate · doi:10.22239/2317-269x.00668
Prevention and Treatment of Yeast and Endemic Fungal Infections
Hammadi, A. A., Ostrosky-Zeichner, L. L., & Baddley, J. W. (2019) · Springer eBooks · doi:10.1007/978-3-030-15394-6_13
The Threat of Multiresistant Nosocomial Fungi
Chai, L. Y., & Tambyah, P. A. (2018) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v47n7p241
A Syk/CARD9 szignalizáció szerepe a Candida parapsilosis immunológiai felismerésében
Zajta, E. (2020) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.10576
Candida: A Model Fungus to Study Differentiation, Pathogenesis, and Bioprospecting
Pathan, E. K., & Deshpande, M. V. (2021) · Springer eBooks · doi:10.1007/978-981-16-3307-2_13
Collins, C., & Rogers, T. R. (2011) · Springer eBooks · doi:10.1007/978-88-470-1601-9_7
Speciation and antifungal susceptibility pattern of Candida isolated from blood and body fluids
Kaur, K., & Aijaz, N. (2023) · Indian Journal of Microbiology Research · doi:10.18231/j.ijmr.2023.003
Ngouana, T. K. (2014) · theses.fr (ABES) · doi:10.70675/890a9294z9feez458bz80aez79384ca8d343 · Cited by 4
Meradji, A., Ranque, S., Bachtarzi, F., MOSBAH, N., & Moulahem, T. (2023) · doi:10.3390/ecm2023-16684 · Cited by 1
Hong, S. B. (2024) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2024.30.2.73
ECHINOCANDINS ARE A NEW CLASS OF ANTIFUNGAL AGENTS FOR THE TREATMENT OF FUNGAL INFECTIONS
Amangeldi, A., САДАНОВ, А. К., Baimakhanova, B. B., Balgimbaeva, A. S., LAKHK, O. N., ОРАЗЫМБЕТ, С. Э., Trenozhnikova, L. P., Кулмагамбетов, И. Р., DAURENBEKOVA, S. Z., & MIRALIMOVA, S. M. (2024) · МИКРОБИОЛОГИЯ ЖӘНЕ ВИРУСОЛОГИЯ · doi:10.53729/mv-as.2024.04.04
Isolate Specific Transcriptome Changes Exerted by Isavuconazole Treatment in Candida auris
Balla, N., Kovács, F., Tóth, Z., Harmath, A., Bozó, A., Majoros, L., Kovács, R., & Jakab, Á. (2024) · Mycopathologia · doi:10.1007/s11046-024-00919-1 · Cited by 1
Saleem, M., Khaja, A. S. S., Moursi, S. A., Mohammed, G. E. Y., Shahid, S. M. A., Hammam, S. A. H., Parveen, N., & Afreen, S. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102855
Pawar, K., & Singh, A. K. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002083 · Cited by 1
Unmasking Candidiasis: A Mechanistic Model for Innate Immune-Fungal Cell Wall Dynamics
Hidu, E. E. (2012) · DigitalCommons (California Polytechnic State University)
Fonctions et biosynthèse des β-1,6-glucanes de la paroi cellulaire chez Candida albicans
Bekirian, C. (2024) · theses.fr (ABES) · doi:10.70675/b1028289z0c26z4acaz8f96z18e5c0c94464
Developing a novel antifungal strategy against a deadly emerging fungal superbug
Dawi, H. (2024) · theses.fr (ABES) · doi:10.70675/4a0e5589z5b0fz4fcczbabez67f52392108d
Epidemiological and genotypic analysis of Candida albicans outbreak in a neonatal ward
Yu, X., Liang, J., Zheng, D., Cao, C., & Wang, S.-J. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13610-1
Candidemia en el Instituto Médico La Floresta. Años 2008-2016
Calderón, X. M., Estévez, C. M., Cáceres, A. M., Guevara, R. N., Guzmán, M. E., & Figuera, M. (2022) · ACTA CIENTIFICA DE LA SOCIEDAD VENEZOLANA DE BIOANALISTAS ESPECIALISTAS
Venkalaisuratha, M., Shyamala, K., & Maniselvi, T. M. (2025) · International Journal of AYUSH · doi:10.22159/prl.ijayush.v14i08.1499
Tiwari, P., Rai, A. K., Varnika, S., Gupta, M. K., Tilak, R., & Paik, P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.06.757060
Metadata
- Authors
- Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M.
- Affiliations
- JMI Laboratories (US)
- Tufts University (US)
- Corresponding author
- Castanheira, Mariana
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-02
- Volume
- 55
- Issue
- 2
- Pages
- 561-566
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3028787
- OpenAlex
- W2103765663
- Cited by
- 238
- References
- 49
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 9 · 2023: 9 · 2022: 9 · 2021: 12 · 2020: 7 · 2019: 25 · 2018: 11 · 2017: 18 · 2016: 24 · 2015: 24 · 2014: 20 · 2013: 20 · 2012: 20
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- candidemia, nosocomial bloodstream infection, Candida species distribution, antifungal resistance, echinocandin resistance, azole resistance, Candida glabrata, Candida albicans, Candida parapsilosis, Candida tropicalis, Candida krusei, SENTRY Antimicrobial Surveillance Program, MIC breakpoints, fluconazole
- MeSH terms
- Antifungal Agents, Azoles, Candida, Candidiasis, Cross Infection, Humans, Microbial Sensitivity Tests, Population Surveillance, Species Specificity, Global Health, Community-Acquired Infections, Drug Resistance, Fungal, Echinocandins, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.